Cushing's disease (pituitary ACTH-secreting adenoma)

What changes during this transition

Cushing's disease is the disease the peptide community most frequently mis-frames, because the failure mode is consistent: 'adrenal support,' 'HPA-axis healing,' 'cortisol balancing,' and 'metabolic optimization' all collapse cortisol-axis pathologies into one bucket where they don't belong. Cushing's disease is cortisol EXCESS from a pituitary tumor. CAH is cortisol deficiency from an enzymatic block with compensatory ACTH-driven adrenal hyperplasia. Addison's is cortisol deficiency from adrenal failure. 'Adrenal fatigue' isn't a recognized endocrine entity and the things people describe as 'adrenal fatigue' overlap with depression, sleep disorders, iron deficiency, hypothyroidism, and a dozen other etiologies that don't share a treatment plan. Lumping any of these together — and offering the same peptide adjuncts to all of them — is the editorial failure mode this entry exists to make harder. The presentation in Cushing's disease is characteristic when full: central obesity with relatively thin extremities, moon facies, dorsocervical fat pad ('buffalo hump'), supraclavicular fat pads, violaceous striae wider than 1 cm (the width and color matter — pregnancy and rapid weight-gain striae look different), thin atrophic skin with easy bruising, hirsutism and acne (from adrenal androgen co-secretion), hypertension, severe insulin resistance frequently progressing to T2D, accelerated osteoporosis with silent vertebral compression fractures (lateral spine imaging matters because patients often don't report fracture pain), proximal muscle weakness (difficulty rising from a chair, climbing stairs), and psychiatric features ranging from depression and anxiety to frank psychosis and significant cognitive impairment. Cushing's mortality is 4-5x the general population when untreated, with cardiovascular disease, thromboembolism, and infection as the leading drivers. This is not a mild condition managed with lifestyle medicine. Diagnosis is staged. Screening uses three independent tests — 24-hour urinary free cortisol, late-night salivary cortisol, and 1 mg overnight dexamethasone suppression — with at least two abnormal results required for confirmation. Pseudo-Cushing's must be excluded, because chronic heavy alcohol use, severe major depression, poorly controlled obesity with metabolic syndrome, and exogenous glucocorticoid exposure (including inhaled, topical, intra-articular, and 'natural' herbal preparations adulterated with steroids) all produce overlapping biochemical pictures. Once Cushing's is confirmed biochemically, localization separates ACTH-dependent (pituitary or ectopic) from ACTH-independent (adrenal) disease via plasma ACTH measurement, high-dose dexamethasone suppression, pituitary MRI, and — when imaging is negative or ambiguous — inferior petrosal sinus sampling, which is the gold standard for confirming a pituitary source. CT chest/abdomen/pelvis is the ectopic ACTH workup. Standard of care is anchored by transsphenoidal pituitary surgery as first-line definitive therapy, with cure rates of 65-90% for microadenomas and 30-65% for macroadenomas at high-volume pituitary centers — and the 'high-volume' qualifier is load-bearing, because surgical outcomes correlate strongly with surgeon and center volume in pituitary disease. Stereotactic radiosurgery (Gamma Knife) is the standard option for residual or recurrent disease after surgery. Medical therapy has expanded substantially in the last decade: osilodrostat (Isturisa, FDA Mar 2020 via LINC-2/3/4), levoketoconazole (Recorlev, FDA Dec 2021), metyrapone, ketoconazole, mifepristone (Korlym, FDA 2012 hyperglycemia), pasireotide (Signifor, FDA 2012 SSTR5), and now relacorilant (Corcept's selective GR antagonist) which hit primary endpoint in Phase 3 GRACE 2024 with FDA submission underway. Bilateral adrenalectomy is the definitive option for refractory disease. Post-surgical cure brings its own recovery arc — cortisol-withdrawal syndrome and adrenal insufficiency requiring exogenous hydrocortisone replacement. The peptide community offerings that show up in Cushing's contexts — BPC-157 'adrenal healing,' NMN 'metabolic support,' GH secretagogues (CJC-1295, ipamorelin, tesamorelin, MK-677) for the body-composition and recovery phenotype — all run into the same set of editorial problems. None of them have Cushing's disease trials in any jurisdiction at any phase. The 'adrenal' framings collapse cortisol-axis pathologies that are mechanistically opposite. The GH secretagogues raise a pituitary-context concern that doesn't apply to most secretagogue conversations: the patient already has a pituitary adenoma, the proposed intervention is sustained pituitary stimulation, and the population of corticotroph-adenoma patients on chronic GHRH or GHSR-1a agonism isn't characterized in any trial. The standard endocrinology approach to post-Cushing's GH deficiency, when confirmed and symptomatic, is recombinant human GH replacement under pituitary endocrinologist supervision with MRI surveillance and IGF-1 targeting — and that's a recognized indication that doesn't have a secretagogue parallel-track equivalent. The load-bearing point is that Cushing's disease is a disease of high-volume pituitary surgery centers, experienced pituitary endocrinologists, careful biochemical workups that include pseudo-Cushing's exclusion, and a medical therapy decision tree that's expanded substantially and continues to expand. The patient resource ecosystem — Cushing's Support and Research Foundation, Pituitary Network Association, American Association of Neurological Surgeons — exists because navigating diagnosis and treatment selection requires advocacy and connection to specialized care. The peptide community isn't part of that ecosystem and shouldn't be inserted into it.